cosibelimab   Click here for help

GtoPdb Ligand ID: 13676

Synonyms: CK-301 | CK301 | cosibelimab-ipdl | Unloxcyt®
Approved drug
cosibelimab is an approved drug (FDA (2024))
Compound class: Antibody
Comment: Cosibelimab (CK-301) is a human anti-programmed cell death 1 ligand 1 (PD-L1) monoclonal antibody. It belongs to the immune checkpoint inhibitor class of anti-tumour drugs. Cosibelimab blocks inhibitory PD-L1 regulation of the anti-tumour immune response and induces antibody-dependent cell-mediated cytotoxicity (ADCC).
Peptide sequence alignments indicate identity between peptide sequences for the INN cosibelimab and those for antibody CTI-48 as claimed in patent US10590199B2 [1].
Bioactivity Comments
Binding affinities for PD-L1 presented here are for antibody CTI-48 as claimed in patent US10590199B2 [1].
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
programmed cell death 1 ligand 1 Monkey Antibody Binding 9.3 pKd - 1
⤷ pKd 9.3 (Kd 5.6x10-10 M) [1]
programmed cell death 1 ligand 1 Primary target of this compound Hs Antibody Binding 9.1 pKd - 1
⤷ pKd 9.1 (Kd 8.5x10-10 M) [1]